Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-02-23 Annual Report
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Annual Report 2022
Annual Report Classification · 100% confidence The document is a 'Full Year Report' for the period January-December 2022. It contains comprehensive financial data, including net sales, operating loss, loss after tax, loss per share, and balance sheet items like cash and cash equivalents. It also includes detailed management commentary, business updates, and project portfolio status. Since it covers a full fiscal year and provides substantive financial statements and analysis, it is classified as an Annual Report (10-K). FY 2022
2023-02-23 English
Cantargia startar randomiserad del i TRIFOUR-studien baserat på lovande tidig säkerhet och effekt med nadunolimab i trippelnegativ bröstcancer
Regulatory Filings Classification · 95% confidence The document is a press release ("Pressmeddelande") dated February 23, 2023, announcing positive early safety and efficacy signals for the drug nadunolimab in the TRIFOUR clinical trial for triple-negative breast cancer (TNBC). It details preliminary response rates (50%) compared to standard chemotherapy and announces the expansion into a randomized Phase II part of the study. This type of announcement, detailing clinical trial progress and preliminary results, is characteristic of an Earnings Release (ER) or a general announcement related to company operations and results. Since it is a formal announcement of financial/operational results (clinical trial data), and not a full regulatory report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as these often include key operational updates alongside financial figures, or in biotech, clinical milestones serve as the primary 'results' announcement. It is not a transcript (CT), a formal annual report (10-K), or a simple notice of dividend (DIV). It is a release of key period results.
2023-02-23 Swedish
Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer
Earnings Release Classification · 99% confidence The document is a press release dated February 23, 2023, reporting on the favorable safety and promising early efficacy results of the clinical trial TRIFOUR involving the drug nadunolimab for triple-negative breast cancer (TNBC). It details response rates, safety profiles, and the progression of the trial to the randomized phase II part. The text concludes with a statement indicating that the information is made public pursuant to the EU Market Abuse Regulation and provides contact information. This content structure—a formal announcement of recent operational/clinical progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses specifically on clinical trial updates and operational progress rather than just financial figures (which would lean towards ER), and it is a formal announcement required for market transparency (EU MAR), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if the company typically bundles such news here. Given the focus on clinical trial advancement and the explicit mention of EU Market Abuse Regulation compliance, RNS (Regulatory Filings) is the most appropriate general category for this type of non-standardized, material operational update. Q1 2023
2023-02-23 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding percentage for a specific instrument, listing the 'Before the transaction' and 'After the transaction' quantities, and noting the 'Reason for major shareholding notification' (Share loan). It explicitly mentions the resulting percentage (5.13221%) and the total voting rights, which is the core function of a Major Shareholding Notification. The filing date is February 7, 2023. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (3664 chars), but the content is the notification itself, not an announcement of a report, thus MRQ is preferred over RPA/RNS.
2023-02-07 English
Cantargia meddelar rekrytering av Patrik Renblad som Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the recruitment of a new Chief Financial Officer (CFO), Patrik Renblad, and thanking the outgoing CFO. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'. The filing type code for this is MANG.
2023-02-01 Swedish
Cantargia announces appointment of Patrik Renblad as Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing a specific change in senior personnel: the appointment of Patrik Renblad as the new Chief Financial Officer (CFO) and thanking the outgoing CFO. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2023-02-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.